Compounds supports hematopoietic stem cells and red blood cells

Patent metadata

Field	Value
Publication number	US-11013704-B2
Application number	US-201515312790-A
Country	US
Kind code	B2
Filing date	May 12, 2015
Priority date	May 28, 2014
Publication date	May 25, 2021
Grant date	May 25, 2021

Abstract

The present disclosure relates to methods of using a compound to induce regeneration of hematopoietic stem cells or increase the recovery of red blood cells. In some aspects, the present methods can be used to with or in place of erythropoietin in patients to mitigate the side effects of erythropoietin.

First claim

What is claimed is:

1. A method of promoting regeneration of hematopoietic stern cells in a patient in need of regeneration of hematopoietic stem cells comprising administering to the patient a pharmaceutically effective amount of a compound in a substantially isolated or purified form and has the formula:

wherein carbon 1 is in the R configuration, S configuration, or a mixture thereof; or a pharmaceutically acceptable salt or optical isomer thereof, wherein the compound is not comprised in a toad skin extract.

2. The method according to claim 1 , wherein the regeneration of hematopoietic stem cells results in an increase in red blood cells.

3. The method according to claim 1 , wherein the compound is administered with a surgery or second drug known to decrease the production of red blood cells.

4. The method of claim 3 , wherein the compound is coadministered with the second drug selected from a chemotherapeutic agent, a radiotherapeutic agent, atovaquone, azacitidine, bexarotene, boceprevir, bosentan, bosutinib, brentuximab vedotin, carbidopa-levodopa, carglumic acid, decitabine, eribulin mesylate, foscarnet, metformin, ofatumumab, pomalidomide, prelatrexate solution, ropivacaine, rosiglitazone, sirolimus, temsirolimus, and valganciclovir.

5. The method of claim 3 , wherein the compound mitigates or prevents the decrease in the production of red blood cells caused by the surgery or second drug.

6. The method according to claim 1 , wherein the compound comprises 80% of the total mass of the substantially isolated or purified form.

7. The method of claim 1 , wherein the compound comprises 90% of the total mass of the substantially isolated or purified form.

8. The method of claim 1 , wherein carbon 1 is in the R configuration.

9. The method of claim 1 , wherein carbon 1 is in the S configuration.

10. The method of claim 1 , wherein carbon 1 comprises a mixture of formulas in the R and S configuration.

Assignees

• Univ Texas

Inventors

• Zhang Chengcheng
• Liu Yi
• Zheng Junke
• Deng mi
• Chen Chuo
• Liu Jiawei

Classifications

• C12N5/0634

  Cells from the blood or the immune system · CPC title

• A61K31/20

  having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids · CPC title

• C07C279/14

  being further substituted by carboxyl groups · CPC title

• A61P7/06

  Antianaemics · CPC title

• A61K31/194 Primary

  having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid · CPC title